Recent events
Recent events tied to this brand in public sources.
Back to profile6 entries
2021
Strides receives renewed EU GMP certificate for Puducherry facility
Strides Pharma Science said it received a renewed GMP certificate for its Puducherry facility after the EU GMP inspection was successfully closed.
2021
Strides and Ennaid enter an exclusive manufacturing partnership
Strides Pharma Science announced that its wholly owned subsidiary Strides Pharma Global entered an exclusive partnership with Ennaid Therapeutics to produce an oral repurposed medication for COVID-19; Strides will be the product's exclusive manufacturing partner.
2020
Strides Pharma recalls Tacrolimus capsules in the US
Strides Pharma Inc, a subsidiary of Strides Pharma Science, initiated a US recall of 960 bottles of Tacrolimus capsules after the FDA cited failed moisture limits. The FDA classified the recall as Class III.
2020
Strides reports Q4FY20 and FY20 results
Strides Pharma Science announced its Q4 and FY20 results, reporting FY20 adjusted revenue of Rs. 29,127 million and adjusted EBITDA of Rs. 6,514 million. The company also recommended a dividend of Rs. 2 per share.
2020
Strides commercializes favipiravir antiviral tablets
Strides Pharma Science announced that it had developed and commercialized favipiravir antiviral tablets in 200 mg and 400 mg strengths. The tablets were being exported to GCC countries, and Strides said it would apply to Indian drug authorities to begin studies and make the drug available in India.
2020
Strides appoints R Ananthanarayanan as CEO and MD
Strides Pharma Science said its board appointed R Ananthanarayanan as Chief Executive Officer and Managing Director, effective January 9. He was to succeed Arun Kumar.